Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma

✍ Scribed by Navid, F.; Sondel, P. M.; Barfield, R.; Shulkin, B. L.; Kaufman, R. A.; Allay, J. A.; Gan, J.; Hutson, P.; Seo, S.; Kim, K.; Goldberg, J.; Hank, J. A.; Billups, C. A.; Wu, J.; Furman, W. L.; McGregor, L. M.; Otto, M.; Gillies, S. D.; Handgretinger, R.; Santana, V. M.

• Book ID: 126849383
• Publisher: American Society of Clinical Oncology
• Year: 2014
• Tongue: English
• Weight: 247 KB
• Volume: 32
• Category: Article
• ISSN: 0732-183X
• DOI: 10.1200/jco.2013.50.4423